Plus Therapeutics announces 1-for-15 reverse stock split to regain Nasdaq compliance

PLUS THERAPEUTICS, INC.

Reverse split ratio 1-for-15 effective 12:01 a.m. ET on May 1, 2023; symbol PSTV unchanged.
Outstanding shares reduced from ~37.4M to ~2.49M; new CUSIP 72941H509.
Purpose is to raise per-share price above Nasdaq's $1.00 minimum bid requirement.
No fractional shares issued; cash payment in lieu for fractional interests.
Equity awards and warrants adjusted proportionately; par value remains $0.001 per share.

item 3.03 item 5.03 item 5.07 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

PLUS THERAPEUTICS, INC.: Amendment to the Amended and Restated Certificate of Incorporation to effect a 1-for-15 reverse stock split of common stock (effective 2023-05-01).

Change: charter amendment
Effective: 2023-05-01

Exact text from the filing

On April 27, 2023, the Company filed a certificate of amendment to its Charter (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, to implement the 1-for-15 reverse split of its common stock (the “Reverse Stock Split”). The Reverse Stock Split will be effective as of 12:01 a.m. (Eastern time) on May 1, 2023, and the Company’s common stock will begin trading on The Nasdaq Capital Market on a post-split basis on May 1, 2023.

View on SEC.gov

Browse all governance changes →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-127227

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.